ANAVEX 2-73 Restores Mitochondrial Functionality, Blocks Cell Death and Oxidative Stress, Preventing Onset of Alzheimer’s Disease

New data presented at International Conference on Alzheimer’s and Parkinson’s Diseases Vancouver, BC — March 12, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today announced more promising new data for ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s disease. In a scientific study conducted in France at the University of Montpellier and…

Anavex Retains Novak Druce Connolly Bove & Quigg to Maximize Value of Intellectual Property Portfolio

Vancouver, BC — February 4, 2013 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) is pleased to announce that it has retained specialized intellectual property law firm Novak Druce Connolly Bove & Quigg LLP (“Novak Druce”) to assist in maximizing the value of the company’s intellectual property (IP) portfolio.  One of the largest IP boutique…

ANAVEX 2-73 Shown to Block Oxidative Stress, Preventing Onset of Alzheimer’s Disease

Data presented at Neuroscience 2012 Vancouver, BC — October 18, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today unveiled more promising new data regarding ANAVEX 2-73, the company’s drug candidate for the treatment and modification of Alzheimer’s disease currently in human clinical trials. The confidential status of the new ANAVEX 2-73 data has been…

Anavex Recognizes Alzheimer’s Action Day

New York, NY — September 21, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCQB: AVXL) today joins the Alzheimer’s Association® in recognizing September 21st as Alzheimer’s Action Day. September is World Alzheimer’s Month.  In the United States alone, Alzheimer’s disease afflicts more than five million people and affects millions more husbands, wives, children, grandchildren, and…

Anavex Presents Compelling Data at World’s Largest Alzheimer’s Conference

Vancouver, BC — July 17, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced new and dramatic data concerning its Alzheimer’s disease treatment candidate ANAVEX 2-73 and leading Alzheimer’s treatments Aricept® (donepezil HCl) and Namenda® (memantine HCl).A clear synergic effect of ANAVEX 2-73 with Aricept® (donepezil HCl) has been demonstrated in a scientific…

Anavex to Present at Alzheimer’s Association International Conference

Vancouver, BC — July 9, 2012 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease currently in human clinical trials, will be presented in a poster session at the 2012 Alzheimer’s Association International Conference (AAIC) in Vancouver, BC, Canada. The ANAVEX…